Claim Missing Document
Check
Articles

Found 2 Documents
Search

Cohort Patient Evaluation of Lung Condition 9 Months after Severe Covid 19 Mahendra, Reza Aditya; Rakhma , Sastia; Sugiri, Yani Jane Rosihaningsih; Djajalaksana, Susanthy; Erawati, Dini Rachma
Malang Respiratory Journal Vol. 7 No. 1 (2025): March 2025 Edition
Publisher : Universitaas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.mrj.2025.007.01.02

Abstract

Introduction: COVID-19 is an infection caused by novel coronavirus Serious Acute Respiratory Syndrome (SARS)-CoV-2. About 20% patients with severe symptoms could become critically ill. In this case report, we present a case with severe COVID-19 infection. Case report: Mr. SA, a 54-year-old patient came to the hospital with chief complaint of dry cough. Patient had fever for 2 days and myalgia. Patient had a history of well-controlled hypertension. X-ray examination showed worsening consolidation and CT-scan showed pleural effusion. Patient was treated with convalescent plasma therapy, IVIG, and symptomatic drugs. The patient was diagnosed with confirmed case of severe COVID-19, stage I hypertension, hypercoagulable state, CCS, and grade I obesity. The Evaluation of this patient consist of CT Scan, Lung Function using a Body Plethysmograph that will followed for 9 month after the patient discharged. Conclusion: There had been a few therapeutic options for COVID-19 but no definitive treatment yet. IVIG and convalescent plasma had been used for the treatment of SARS-CoV and MERS-CoV. As such, these treatments were also used in COVID-19 treatment with promising results. Keywords: COVID-19, IVIG, convalescent plasma
The Influence of Nigella sativa on the Increase of IFN-γ and Quality of Life in Lung Cancer Patients Undergoing Chemotherapy Mahendra, Reza Aditya; Pratiwi, Suryanti Dwi; Sartono, Teguh Rahayu; Rakhma, Sastia; Setijowati, Nanik
Jurnal Respirasi Vol. 11 No. 1 (2025): January 2025
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v11-I.1.2025.31-38

Abstract

Introduction: In vitro and animal model studies have shown that Nigella sativa reduces cancer cell proliferation and improves chemotherapy effectiveness. Cellular activation triggers the production of IFN-γ by natural killer (NK) cells. This study examined the effect of Nigella sativa supplementation on IFN-γ levels and quality of life in lung cancer patients before and after interferon therapy. Methods: This study used a non-equivalent control experimental design involving 21 lung cancer patients undergoing initial chemotherapy at Dr. Saiful Anwar General Hospital, Malang, in 2023. The patients were divided into two groups: one group received standard chemotherapy, and another group received a combination of chemotherapy and Nigella sativa supplementation at a dose of 2x500 mg for nine weeks. The effects of this intervention were assessed by measuring IFN-γ levels using an enzyme-linked immunosorbent assay (ELISA) kit and evaluating quality of life using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QLQ-C30) questionnaire before and after the fourth cycle of chemotherapy. Results: The results showed a significant increase in IFN-γ levels in the combination group undergoing chemotherapy and receiving Nigella sativa supplementation (6140.44±2233.89) compared to the standard chemotherapy group (3827.08±1722.79), with a p-value of 0.015. Quality of life improved in both groups, with scores of 53.70±6.05 before and 65.74±14.70 after chemotherapy (p=0.000). Conclusion: This study found that Nigella sativa supplementation can enhance IFN-γ levels and quality of life in lung cancer patients after four chemotherapy treatment cycles. These findings indicated that Nigella sativa could be a beneficial supplement for lung cancer patients.